Nigel is responsible for Cancer Research UK’s early drug development activity, translating novel agent scientific programmes through to clinic. Currently, Nigel and his team at CR-UK Centre for Drug Development manage a diverse portfolio of ~16 novel agents at various stages of development from GMP production, regulatory preclinical studies, through to first-in-human, phase I and early phase II clinical trials. Nigel joined Cancer Research UK in May 2009, having previously worked in a variety of senior management roles in the pharma and biotech sectors
